Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22322
Title: Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?
Austin Authors: Arulananda, Surein;John, Thomas 
Affiliation: Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Heidelberg, Australia
Department of Medical Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Issue Date: Jan-2020
Publication information: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020; 15(1): 12-14
URI: http://ahro.austin.org.au/austinjspui/handle/1/22322
DOI: 10.1016/j.jtho.2019.10.017
ORCID: 0000-0002-5636-6381
PubMed URL: 31864546
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Dec 7, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.